Evaluation of Efficacy and Tolerability of Cefotaxime and Sulbactam Versus Cefepime and Tazobactam in Patients of Urinary Tract Infection-A Prospective Comparative Study

Kaur, Kamalpreet; Gupta, Anita; Sharma, Anmol; Walia, Geeta; Singh, Baldev

doi:10.7860/jcdr/2014/9742.5090

Cited by 6 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a study by Xin et al, the ceftriaxone/sulbactam combination eradicated 83.6% of various organisms in urinary tract infections [ 22 ]. Cefotaxime-sulbactam was found to be effective in the treatment of lower respiratory and urinary tract infections [ 27 , 28 ]. The high efficacy of cefotaxime/sulbactam in adults and children in the treatment of pneumonia, peritonitis, and urinary tract infections, as well as skin and soft tissues, has been shown in four clinical studies conducted in Russia and other countries [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

An In Vitro Susceptibility Study of Cefotaxime-Sulbactam on Clinical Bacterial Isolates From Various Regions in India: A Comparison With Ceftriaxone-Sulbactam

Gondane¹,

Pawar²

2023

Cureus

View full text Add to dashboard Cite

Background and objective Combining sulbactam with cefotaxime/ceftriaxone augments its antimicrobial activity against β-lactamase-producing bacteria. They are widely used as empirical treatment for many clinical infections. However, there is a scarcity of data on the susceptibility of various organisms to these antibiotics in the Indian region. In light of this, the present in vitro study evaluated the susceptibility of bacterial isolates to cefotaxime-sulbactam and compared it with ceftriaxone-sulbactam. Methodology Clinical samples with positive bacterial cultures from various laboratories in India were subjected to antibiotic sensitivity testing using in vitro E-test strips and disk diffusion methods to determine the minimum inhibitory concentration (MIC) and zone of inhibition (ZOI), respectively. MIC 50 and MIC 90 values were determined along with the measurement of the ZOI for the effectiveness of antibiotics. Interpretations of MIC and ZOI values were made as per the criteria set by the Clinical and Laboratory Standards Institute (CLSI) guidelines to estimate the proportion of sensitive organisms. Results Among 400 clinical isolates evaluated, Escherichia coli (E. coli) (47.75%) was the most common organism isolated followed by Klebsiella (26%), Salmonella (7.75%), Proteus (3.8%), and Acinetobacter (2.8%). The mean ZOI was found significantly higher for E. coli, Klebsiella, and Salmonella in the cefotaxime-sulbactam group than in the ceftriaxone-sulbactam group. MIC 50 values for E. coli and Klebsiella were 0.25 and 0.19 µg/ml, respectively in the cefotaxime-sulbactam group as compared to 0.38 and 0.25 µg/ml, respectively for ceftriaxone-sulbactam. The proportion of sensitive isolates was also higher in the cefotaxime-sulbactam group for E. coli, Klebsiella , and Salmonella . Conclusions The in vitro effect of cefotaxime-sulbactam on organisms is similar to that of ceftriaxone-sulbactam in terms of MIC, ZOI, and proportion of sensitivity based on our study involving clinical isolates from various parts of India. Cefotaxime-sulbactam may be preferred in the empirical management of various clinical infections.

show abstract

Section: Discussionmentioning

confidence: 99%

An In Vitro Susceptibility Study of Cefotaxime-Sulbactam on Clinical Bacterial Isolates From Various Regions in India: A Comparison With Ceftriaxone-Sulbactam

Gondane¹,

Pawar²

2023

Cureus

View full text Add to dashboard Cite

show abstract

“…-6,6%). Общая эффективность терапии в группе цефотаксима/сульбактама составила 89,3 ± 9,1%, в группе препарата сравнения -94,5 ± 5,1% [14].…”

Section: клинические исследования эффективности и безопасности цефотаunclassified

Cefotaxime/sulbactam: clinical and pharmacological characteristics

Ортенберг¹,

Голуб²

2019

CMAC

View full text Add to dashboard Cite

1 ФГБОУ ВО «Тюменский государственный медицинский университет» Минздрава России, Тюмень, Россия 2 ФГБОУ ВО «Смоленский государственный медицинский университет» Минздрава России, Смоленск, Россия Резистентность возбудителей инфекций человека к антимикробным препаратам, реализуемая с помощью продукции бета-лактамаз, является серьезной проблемой современного здравоохранения. Цефотаксим/сульбактам -комбинированный ингибиторозащищенный цефалоспорин III поколения, недавно ставший доступным в России, -способен преодолевать механизмы устойчивости, связанные с синтезом сериновых бета-лактамаз, в т.ч. и некоторых ферментов расширенного спектра. В обзоре обсуждаются аспекты применения препарата в клинической практике с учетом актуальных данных по антибиотикорезистентности возбудителей инфекций нижних дыхательных путей, а также результатов клинических исследований его эффективности и безопасности. Контактный адрес: Алексей Викторович Голуб Эл. почта: Alex.Golub@antibiotic.ru Ключевые слова: цефалоспорины III поколения, сульбактам, цефотаксим/ сульбактам, антибиотикорезистентность, инфекции нижних дыхательных путей, инфекции мочевых путей.

show abstract

“…The combined administration of CTX and SBT can avoid the resistance of pathogenic bacteria to CTX and improve the antibacterial effect ( 14 ). Cefotaxime sodium - sulbactam sodium (CTX-SBT) combined administration is commonly used in diverse bacterial infections ( 15 ). However, DIIHA caused by CTX and SBT has been reported in some cases ( 2 , 16 , 17 ), and DIIHA caused by CTX-induced drug-dependent antibodies can cause intravascular hemolysis although it is rare ( 16 ), while SBT can only through the NIPA mechanism cause positive direct anti-globulin tests (DAT) results and slow extravascular hemolysis that is difficult to observe ( 2 , 3 ).…”

Section: Introductionmentioning

confidence: 99%

Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption

Wu²,

Bao-chan³

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

BackgroundABO blood type incompatibility hemolytic disease of newborn (ABO-HDN) and drug-induced immune hemolytic anemia (DIIHA) due to non-immunologic protein adsorption (NIPA) mainly cause extravascular hemolysis. All the reported severe DIIHA were caused by drug-induced antibodies, and rare report of acute intravascular hemolysis was caused by the NIPA mechanism or ABO-HDN.Case presentationWe report the first case of acute intravascular hemolysis induced by cefotaxime sodium - sulbactam sodium (CTX - SBT) in a case of ABO-HDN which resulted in death at 55 h after birth. The mother’s blood type was O and RhD-positive, and the newborn’s blood type was B and RhD-positive. No irregular red blood cell (RBC) antibodies or drug-dependent antibodies related to CTX or SBT was detected in the mother’s plasma and the plasma or the RBC acid eluent of the newborn. Before the newborn received CTX - SBT treatment, the result of direct antiglobulin test (DAT) was negative while anti-B was positive (2 +) in both plasma and acid eluent. After the newborn received CTX - SBT treatment, the results of DAT for anti-IgG and anti-C3d were both positive, while anti-B was not detected in plasma, but stronger anti-B (3 +) was detected in acid eluent. In vitro experiments confirmed that NIPA of SBT promoted the specific binding of maternal-derived IgG anti-B to B antigen on RBCs of the newborn, thereby inducing acute intravascular hemolysis.ConclusionThe NIPA effect of SBT promoted the specific binding of mother-derived IgG anti-B in newborn’s plasma to the newborn’s RBC B antigens and formed an immune complex, and then activated complement, which led to acute intravascular hemolysis. Drugs such as SBT with NIPA effect should not be used for newborns with HDN.

show abstract

Evaluation of Efficacy and Tolerability of Cefotaxime and Sulbactam Versus Cefepime and Tazobactam in Patients of Urinary Tract Infection-A Prospective Comparative Study

Cited by 6 publications

References 22 publications

An In Vitro Susceptibility Study of Cefotaxime-Sulbactam on Clinical Bacterial Isolates From Various Regions in India: A Comparison With Ceftriaxone-Sulbactam

An In Vitro Susceptibility Study of Cefotaxime-Sulbactam on Clinical Bacterial Isolates From Various Regions in India: A Comparison With Ceftriaxone-Sulbactam

Cefotaxime/sulbactam: clinical and pharmacological characteristics

Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption

Contact Info

Product

Resources

About